HUE064550T2 - A sercát moduláló kinolin és annak alkalmazása betegségek kezelésében - Google Patents

A sercát moduláló kinolin és annak alkalmazása betegségek kezelésében

Info

Publication number
HUE064550T2
HUE064550T2 HUE21845832A HUE21845832A HUE064550T2 HU E064550 T2 HUE064550 T2 HU E064550T2 HU E21845832 A HUE21845832 A HU E21845832A HU E21845832 A HUE21845832 A HU E21845832A HU E064550 T2 HUE064550 T2 HU E064550T2
Authority
HU
Hungary
Prior art keywords
serca
quinoline
modulate
treating disease
disease
Prior art date
Application number
HUE21845832A
Other languages
English (en)
Hungarian (hu)
Inventor
Russell Dahl
Original Assignee
Neurodon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/932,832 external-priority patent/US20200347038A1/en
Application filed by Neurodon Corp filed Critical Neurodon Corp
Publication of HUE064550T2 publication Critical patent/HUE064550T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE21845832A 2020-07-20 2021-07-19 A sercát moduláló kinolin és annak alkalmazása betegségek kezelésében HUE064550T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16/932,832 US20200347038A1 (en) 2014-08-29 2020-07-20 Quinolines that modulate serca and their use for treating disease

Publications (1)

Publication Number Publication Date
HUE064550T2 true HUE064550T2 (hu) 2024-03-28

Family

ID=79729478

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE21845832A HUE064550T2 (hu) 2020-07-20 2021-07-19 A sercát moduláló kinolin és annak alkalmazása betegségek kezelésében

Country Status (11)

Country Link
EP (1) EP4037685B9 (enExample)
JP (1) JP7705445B2 (enExample)
CN (1) CN116744928A (enExample)
CA (1) CA3186668A1 (enExample)
DK (1) DK4037685T3 (enExample)
ES (1) ES2968041T3 (enExample)
FI (1) FI4037685T3 (enExample)
HU (1) HUE064550T2 (enExample)
PL (1) PL4037685T3 (enExample)
PT (1) PT4037685T (enExample)
WO (1) WO2022020261A1 (enExample)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101784533B (zh) * 2007-08-22 2013-08-21 艾博特股份有限两合公司 4-苄基氨基喹啉、含有它们的药物组合物和它们在治疗中的用途
CN104302640A (zh) * 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
US10772881B2 (en) * 2017-02-27 2020-09-15 Russell Dahl Quinolines that modulate SERCA and their use for treating disease
US20170281611A1 (en) * 2014-08-29 2017-10-05 Eiger Biopharmaceuticals, Inc. Quinolines and their use for treating endoplasmic reticulum stress-caused diseases
US20200347038A1 (en) * 2014-08-29 2020-11-05 Russell Dahl Quinolines that modulate serca and their use for treating disease
CN106966973A (zh) * 2017-05-18 2017-07-21 湖北工业大学 N‑苯基‑n‑(2‑甲基‑8‑喹啉基)苯甲酰胺的制备方法

Also Published As

Publication number Publication date
WO2022020261A1 (en) 2022-01-27
JP7705445B2 (ja) 2025-07-09
FI4037685T3 (fi) 2023-11-27
EP4037685A4 (en) 2022-11-30
DK4037685T3 (en) 2024-01-02
EP4037685B1 (en) 2023-09-20
WO2022020261A9 (en) 2022-09-09
CA3186668A1 (en) 2022-01-27
ES2968041T3 (es) 2024-05-06
CN116744928A (zh) 2023-09-12
PT4037685T (pt) 2023-12-28
EP4037685B9 (en) 2024-03-06
PL4037685T3 (pl) 2024-04-02
JP2023534992A (ja) 2023-08-15
EP4037685A1 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
EP3968916A4 (en) GLAND TREATMENT DEVICES AND METHODS FOR TREATMENT OF DRY EYES
IL285649A (en) Azepino-indoles and other heterocyclics for the treatment of brain disorders
IL285734A (en) Devices and methods for treating edema
IL268327A (en) A pharmaceutical preparation for use in the treatment and prevention of c5-related diseases and methods for the treatment and prevention of c5-related diseases
SG11202013239RA (en) Composition and method for treating pain
ZA201905222B (en) Combination treating prostate cancer, pharmaceutical composition and treatment method
IL276247A (en) Methods and materials for the treatment of sleep apnea
PT3810128T (pt) Composições para tratar e/ou prevenir doenças de agregação de proteinas
IL285197A (en) Methods and preparations for the treatment of sleep apnea
IL304273A (en) Compositions and methods for treating Fabry disease
IL275875A (en) Treatment and prevention of sleep disorders
EP4334718A4 (en) CANCER EVALUATION AND TREATMENT
DK4037685T3 (en) Quinoline that modulate serca and its use for treating disease
IL288178A (en) Combined gmci and ddri treatment for cancer
IL309071A (en) Methods and compositions for the treatment of cancer
IL274254A (en) Alkoxyamino derivatives for the treatment of pain and pain-related morbidity
IL291609A (en) Methods for treating acute wounds and improving outcomes
EP4085908A4 (en) PHARMACEUTICAL COMBINATION FOR TREATING TUMORS AND ITS APPLICATION
EP4009964A4 (en) PREVENTION AND TREATMENT OF HYPOGLYCEMIA
GB202101728D0 (en) Compounds and their use treating cancer
HK40113459A (en) Medicament for preventing and/or treating dry eye
HK40104254A (en) Methods and agents that stimulate mitochondrial turnover for treating disease
IL288524A (en) Methods of treatment or prevention of eczema
HK40066255A (en) Preventing and treating hypoglycemia
HK40071066A (en) Gmci and ddri combination therapy for treating cancer